558 related articles for article (PubMed ID: 25865094)
81. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
82. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
[TBL] [Abstract][Full Text] [Related]
83. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.
Lyu C; Zhang Y; Liu X; Wu J; Zhang J
BMC Infect Dis; 2020 Apr; 20(1):296. PubMed ID: 32316926
[TBL] [Abstract][Full Text] [Related]
84. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
[No Abstract] [Full Text] [Related]
85. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
Karakonstantis S; Kritsotakis EI; Gikas A
Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
[TBL] [Abstract][Full Text] [Related]
86. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
[TBL] [Abstract][Full Text] [Related]
87. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii.
Kempf M; Djouhri-Bouktab L; Brunel JM; Raoult D; Rolain JM
Int J Antimicrob Agents; 2012 Feb; 39(2):180-1. PubMed ID: 22100281
[No Abstract] [Full Text] [Related]
88. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007.
Liang-Yu C; Kuo SC; Liu CY; Luo BS; Huang LJ; Lee YT; Chen CP; Chen TL; Fung CP
J Microbiol Immunol Infect; 2011 Oct; 44(5):358-63. PubMed ID: 21524973
[TBL] [Abstract][Full Text] [Related]
89. Antibiotic Resistance Pattern Of Acinetobacter Baumannii Isolated From Bacteremia Patients In Pakistan.
Jabeen F; Khan Z; Sohail M; Tahir A; Tipu I; Murtaza Saleem HG
J Ayub Med Coll Abbottabad; 2022; 34(1):95-100. PubMed ID: 35466635
[TBL] [Abstract][Full Text] [Related]
90. Treatment of multiresistant Acinetobacter baumannii infections.
Pachón J; Vila J
Curr Opin Investig Drugs; 2009 Feb; 10(2):150-6. PubMed ID: 19197792
[TBL] [Abstract][Full Text] [Related]
91. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.
Viehman JA; Nguyen MH; Doi Y
Drugs; 2014 Aug; 74(12):1315-33. PubMed ID: 25091170
[TBL] [Abstract][Full Text] [Related]
92. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
Arroyo LA; Mateos I; González V; Aznar J
Antimicrob Agents Chemother; 2009 Mar; 53(3):1295-6. PubMed ID: 19075049
[No Abstract] [Full Text] [Related]
93. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen.
Shields RK; Kwak EJ; Potoski BA; Doi Y; Adams-Haduch JM; Silviera FP; Toyoda Y; Pilewski JM; Crespo M; Pasculle AW; Clancy CJ; Nguyen MH
Diagn Microbiol Infect Dis; 2011 Jun; 70(2):246-52. PubMed ID: 21353436
[TBL] [Abstract][Full Text] [Related]
94. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis.
Rodríguez-Hernández MJ; Jiménez-Mejias ME; Pichardo C; Cuberos L; García-Curiel A; Pachón J
Clin Microbiol Infect; 2004 Jun; 10(6):581-4. PubMed ID: 15191391
[TBL] [Abstract][Full Text] [Related]
95. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.
Choi SH; Cho EB; Chung JW; Lee MK
J Infect Chemother; 2019 Jan; 25(1):6-11. PubMed ID: 30342838
[TBL] [Abstract][Full Text] [Related]
96. Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
Tuon FF; Rymsza AM; Penteado-Filho SR; Pilonetto M; Arend LN; Levin AS
J Infect; 2011 Mar; 62(3):246-9. PubMed ID: 21256151
[No Abstract] [Full Text] [Related]
97. Successful treatment of postoperative multidrug-resistant Acinetobacter baumannii meningitis by tigecycline.
Kooli I; Brahim HB; Kilani M; Gannouni C; Aouam A; Toumi A; Loussaief C; Hattab MN; Chakroun M
J Glob Antimicrob Resist; 2016 Jun; 5():62-3. PubMed ID: 27436468
[TBL] [Abstract][Full Text] [Related]
98. Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram-Negative Organisms?
Shankar C; Nabarro LEB; Anandan S; Veeraraghavan B
Microb Drug Resist; 2017 Jun; 23(4):437-446. PubMed ID: 27564414
[TBL] [Abstract][Full Text] [Related]
99. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
100. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.
Tal-Jasper R; Katz DE; Amrami N; Ravid D; Avivi D; Zaidenstein R; Lazarovitch T; Dadon M; Kaye KS; Marchaim D
Antimicrob Agents Chemother; 2016 May; 60(5):3127-31. PubMed ID: 26883694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
